Serum β2-microglobulin (β2-M) was measured in 115 patients with systemic lupus erythematosus (SLE) on 192 occasions. Raised β2-M was found in 16.4% of patients with only extrarenal manifestations of SLE, in 29.2% of patients with renal manifestation but an endogenous creatinine clearance >80 ml/min/1.73 m2 and in 65.7% of patients with decreased creatinine clearance. β2-M was higher in SLE than non-SLE glomerulonephritides matched for creatinine clearance. Using an arbitrary scoring system, renal, extrarenal and serological activity correlated with β2-M. Changes in clinical activity on repeat studies were reflected by changes in β2-M. Serum β2-M can serve as a monitor of disease activity in SLE.link_to_subscribed_fulltex
At present, some clinical presentations and serological parameters such as products of complement ac...
Anti-phospholipid antibodies (APA) like anti-cardiolipin antibodies (ACA) and anti-β2glycoprotien (a...
Lupus nephritis (LN) is a severe clinical manifestation of systemic lupus erythematosus (SLE) associ...
Background: Designation of disease activity is serious for the management of systemic lupus erythema...
By the use of radioimmunoassay, urinary β2-microglobulin concentration was mesured in 49 patients wi...
To determine correlations of serum beta 2-microglobulin (β2-MG) level with disease activity and rena...
BACKGROUND: We evaluated whether serum leucine-rich α2-glycoprotein (LRG) is associated with disease...
CONTEXT AND OBJECTIVE: Systemic lupus erythematosus (SLE) is an autoimmune disease with a cyclical c...
Background. Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease that common...
Lupus Nephritis (LN) develops in more than half of the Systemic Lupus Erythematous (SLE) patients. H...
Lupus nephritis (LN) is among the most serious complications of systemic lupus erythematosus (SLE), ...
Systemic lupus erythematosus (SLE) is a chronic, relapsing, polysystemic autoimmune disease with var...
The presence of elevated plasma levels of autoantibodies against Clq, a subcomponent of the first co...
Lupus nephritis (LN) is among the most serious complications of systemic lupus erythematosus (SLE), ...
Abstract- At present, some clinical presentations and serological parameters such as products of com...
At present, some clinical presentations and serological parameters such as products of complement ac...
Anti-phospholipid antibodies (APA) like anti-cardiolipin antibodies (ACA) and anti-β2glycoprotien (a...
Lupus nephritis (LN) is a severe clinical manifestation of systemic lupus erythematosus (SLE) associ...
Background: Designation of disease activity is serious for the management of systemic lupus erythema...
By the use of radioimmunoassay, urinary β2-microglobulin concentration was mesured in 49 patients wi...
To determine correlations of serum beta 2-microglobulin (β2-MG) level with disease activity and rena...
BACKGROUND: We evaluated whether serum leucine-rich α2-glycoprotein (LRG) is associated with disease...
CONTEXT AND OBJECTIVE: Systemic lupus erythematosus (SLE) is an autoimmune disease with a cyclical c...
Background. Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease that common...
Lupus Nephritis (LN) develops in more than half of the Systemic Lupus Erythematous (SLE) patients. H...
Lupus nephritis (LN) is among the most serious complications of systemic lupus erythematosus (SLE), ...
Systemic lupus erythematosus (SLE) is a chronic, relapsing, polysystemic autoimmune disease with var...
The presence of elevated plasma levels of autoantibodies against Clq, a subcomponent of the first co...
Lupus nephritis (LN) is among the most serious complications of systemic lupus erythematosus (SLE), ...
Abstract- At present, some clinical presentations and serological parameters such as products of com...
At present, some clinical presentations and serological parameters such as products of complement ac...
Anti-phospholipid antibodies (APA) like anti-cardiolipin antibodies (ACA) and anti-β2glycoprotien (a...
Lupus nephritis (LN) is a severe clinical manifestation of systemic lupus erythematosus (SLE) associ...